Stay updated with breaking news from Cost Plus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
San Leandro, CA (PRWEB) October 18, 2022 -- VIVIO, a public benefit corporation reinventing the use of drug trial data in care delivery, announces a
SCPH's lead drug candidate FUROSCIX was approved on October 10th by the FDA. To help distribute the drug, SCPH secured a $100 million loan. Read more here.
After earning his doctorate and a medical degree, Dr. Alex Oshmyansky set off on a seemingly impossible quest: disrupt the pharmaceutical industry. Along the way, he was joined by a billionaire maverick. Meet the Mark Cuban Cost Plus Drug Company.
It is Mark Cuban Cost Plus Drug Company's first collaboration with a health plan. The pharmacy company will not be replacing Capital Blue Cross' existing pharmacy benefits manger, but instead will be an additional option for members to choose.
/PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) announced that it has acquired five market-approved anti-cancer drugs approved for...